ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the
UBS 2008 Global Life Sciences Conference on Monday, September 22, 2008
at 9:00 a.m. eastern time.
ArQule’s presentation will be web cast live
and can be accessed through the investor relations section of the Company’s
website, www.arqule.com. The
conference will be held at the Grand Hyatt Hotel, New York.
About ArQule
ArQule is a biotechnology company engaged in the research and
development of next-generation, small-molecule cancer therapeutics. The
Company’s targeted, broad-spectrum products
and research programs are focused on key biological processes that are
central to cancer. ArQule’s lead products,
which are in clinical-stage development, consist of ARQ 197, an
inhibitor of the c-Met receptor tyrosine kinase, and ARQ 501, an
activator of the cell’s DNA damage response
mechanism mediated by the E2F-1 transcription factor. The Company’s
most advanced pre-clinical development programs are focused on ARQ 761,
a second-generation E2F-1 product candidate, as well as compounds that
inhibit the Eg5 kinesin spindle protein and the BRAF kinase. ArQule’s
discovery efforts are focused on the identification of novel kinase
inhibitors that are potent, selective and do not compete with ATP
(adenosine triphosphate), an energy source for cells. For more
information, please visit www.arqule.com.
ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor
Relations/Corp. Communications
www.ArQule.com
